Literature DB >> 31930013

No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases.

Sergio Bracarda1, Claudia Mosillo1, Fabio Trippa2, Federica Urbano1, Ernesto Maranzano2, Claudia Caserta1.   

Abstract

Entities:  

Year:  2019        PMID： 31930013      PMCID： PMC6944575          DOI： 10.21037/atm.2019.11.50

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

Review 1.  Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review.

Authors:  Sergio Bracarda; Camillo Porta; Roberto Sabbatini; Licia Rivoltini
Journal:  Crit Rev Oncol Hematol       Date:  2018-08-01       Impact factor: 6.312

Review 2.  Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.

Authors:  Chiara Ciccarese; Roberto Iacovelli; Claudia Mosillo; Giampaolo Tortora
Journal:  Clin Genitourin Cancer       Date:  2018-06-21       Impact factor: 2.872

3.  Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer.

Authors:  Michael Staehler; Nicolas Haseke; Thomas Stadler; Philipp Nuhn; Alexander Roosen; Christian G Stief; Ralf Wilkowski
Journal:  Urol Oncol       Date:  2010-09-01       Impact factor: 3.498

4.  Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

Authors:  Martin E Gore; Subramanian Hariharan; Camillo Porta; Sergio Bracarda; Robert Hawkins; Georg A Bjarnason; Stéphane Oudard; Se-Hoon Lee; Giacomo Carteni; Alejandra Nieto; Jinyu Yuan; Cezary Szczylik
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

5.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

6.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Authors:  Georgina V Long; Victoria Atkinson; Serigne Lo; Shahneen Sandhu; Alexander D Guminski; Michael P Brown; James S Wilmott; Jarem Edwards; Maria Gonzalez; Richard A Scolyer; Alexander M Menzies; Grant A McArthur
Journal:  Lancet Oncol       Date:  2018-03-27       Impact factor: 41.316

7.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

Authors:  Masaaki Yamamoto; Toru Serizawa; Takashi Shuto; Atsuya Akabane; Yoshinori Higuchi; Jun Kawagishi; Kazuhiro Yamanaka; Yasunori Sato; Hidefumi Jokura; Shoji Yomo; Osamu Nagano; Hiroyuki Kenai; Akihito Moriki; Satoshi Suzuki; Yoshihisa Kida; Yoshiyasu Iwai; Motohiro Hayashi; Hiroaki Onishi; Masazumi Gondo; Mitsuya Sato; Tomohide Akimitsu; Kenji Kubo; Yasuhiro Kikuchi; Toru Shibasaki; Tomoaki Goto; Masami Takanashi; Yoshimasa Mori; Kintomo Takakura; Naokatsu Saeki; Etsuo Kunieda; Hidefumi Aoyama; Suketaka Momoshima; Kazuhiro Tsuchiya
Journal:  Lancet Oncol       Date:  2014-03-10       Impact factor: 41.316

Review 8.  Radiotherapy for renal-cell carcinoma.

Authors:  Gert De Meerleer; Vincent Khoo; Bernard Escudier; Steven Joniau; Alberto Bossi; Piet Ost; Alberto Briganti; Valérie Fonteyne; Marco Van Vulpen; Nicolaas Lumen; Martin Spahn; Marc Mareel
Journal:  Lancet Oncol       Date:  2014-04       Impact factor: 41.316

9.  Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection.

Authors:  Franziska M Ippen; Anand Mahadevan; Eric T Wong; Erik J Uhlmann; Soma Sengupta; Ekkehard M Kasper
Journal:  J Oncol       Date:  2015-11-19       Impact factor: 4.375

10.  Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).

Authors:  Paul Lesueur; Justine Lequesne; Victor Barraux; William Kao; Julien Geffrelot; Jean-Michel Grellard; Jean-Louis Habrand; Evelyne Emery; Brigitte Marie; Juliette Thariat; Dinu Stefan
Journal:  Radiat Oncol       Date:  2018-07-28       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.